DI GIACOMO ANNA MARIA | Professor page

Ascierto, P.a., Del Vecchio, M., Merelli, B., Gogas, H., Arance, A.m., Dalle, S., et al. (2026). Nivolumab for Resected Stage III or IV Melanoma at 9 Years. THE NEW ENGLAND JOURNAL OF MEDICINE [10.1056/NEJMoa2504966]. - view more
Calabrò, L., P Caruso, F., Covre, A., R Noviello, T.M., F Lofiego, M., Tufano, R., et al. (2026). Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study. NATURE GENETICS, 58(5), 1100-1111 [10.1038/s41588-026-02580-4]. - view more
Buhrer, E., Glassee, N., Kicinski, M., Kennedy, O.J., Blank, C.U., Long, G.V., et al. (2025). Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma. EJC SKIN CANCER, 3 [10.1016/j.ejcskn.2025.100727]. - view more
Lofiego, M.F., Tufano, R., Bello, E., Solmonese, L., Marzani, F., Piazzini, F., et al. (2025). Abstract 4841: DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy. In Cancer Research (pp.4841-4841) [10.1158/1538-7445.am2025-4841]. - view more
Di Giacomo, A.M., Subudhi, S., Vos, W., Andreatta, M., Carmona, S., Mctavish, W., et al. (2025). Perspectives on the role of “-Omics” in predicting response to immunotherapy. EUROPEAN JOURNAL OF CANCER, 220 [10.1016/j.ejca.2025.115393]. - view more